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Posttranslational modifications play central roles
in myriad biological pathways including circadian
regulation. We employed a circadian proteomic
approach to demonstrate that circadian timing of
phosphorylation is a critical factor in regulating
complex GSK3b-dependent pathways and identified
O-GlcNAc transferase (OGT) as a substrate of
GSK3b. Interestingly, OGT activity is regulated by
GSK3b; hence, OGT and GSK3b exhibit reciprocal
regulation. Modulating O-GlcNAcylation levels alter
circadian period length in both mice and Drosophila;
conversely, protein O-GlcNAcylation is circadianly
regulated. Central clock proteins, Clock and Period,
are reversibly modified by O-GlcNAcylation to regu-
late their transcriptional activities. In addition,
O-GlcNAcylation of a region in PER2 known to regu-
late human sleep phase (S662–S674) competes with
phosphorylation of this region, and this interplay is at
least partly mediated by glucose levels. Together,
these results indicate that O-GlcNAcylation serves
as a metabolic sensor for clock regulation and works
coordinately with phosphorylation to fine-tune circa-
dian clock.
INTRODUCTION
Circadian rhythms in physiology and behavior are present in
a variety of organisms from plants and bacteria to humans.
These rhythms are controlled by endogenous molecular clocks
even in the absence of external cues (e.g., light). The fact that
circadian clocks are evolutionarily conserved supports the
view that precise rhythms are essential for organisms to survive.
Perturbations of circadian rhythms and sleep have been associ-
ated with many human ailments such as metabolic syndrome,
cardiovascular disease, depression, epilepsy, and cancer
(Bass and Takahashi, 2010; Climent et al., 2010; Duez and
Staels, 2010; Wulff et al., 2010).Cell MGlycogen synthase kinase 3b (GSK3b) is an important sig-
naling mediator that has central functions in diverse physiolog-
ical pathways including transcription, cell-cycle regulation,
metabolism, development, neuronal function, and oncogenesis,
among others (Rayasam et al., 2009). These diverse functions of
GSK3b can be attributed to the large number of substrates it can
phosphorylate. GSK3b is a constitutively active serine/threonine
kinase with a preference for primed substrates and is inactivated
in response to multiple stimuli by phosphorylation at S9 (Cohen
and Frame, 2001). GSK3b is also a crucial circadian clock regu-
lator (Iitaka et al., 2005; Martinek et al., 2001). Lithium (a GSK3b
inhibitor) treatment lengthens the circadian period and delays
the phase of rhythmic clock gene expression (Abe et al., 2000;
Iitaka et al., 2005), although a recent report showed that inhibi-
tion of GSK3b activity by small molecule inhibitors or siRNAs
shortens the circadian period (Hirota et al., 2008). In order to
further understand the effects of GSK3b activity on various
biological pathways in general and circadian regulation in partic-
ular, we employed a proteomic approach to elucidate the com-
plexity of the GSK3b circadian phosphoproteome. Interestingly,
we identified O-GlcNAc transferase (OGT) from the chemical-
genetic proteomic screen as a substrate of GSK3b. GSK3b
was previously shown to be O-GlcNAcylated by OGT in vitro
(Lubas and Hanover, 2000). Since our data suggest that OGT
andGSK3b regulate each other andGSK3b is a critical molecular
clock component, we investigated the possibility of O-GlcNAcy-
lation as a regulatory posttranslational modification in circadian
regulation.
O-linked N-acetylglucosamine (O-GlcNAc) glycosylation has
emerged as one of the most common protein posttranslational
modifications with the second most abundant high-energy
compound, UDP-GlcNAc, as the direct donor. Two enzymes
regulate O-GlcNAcylation: the OGT attaches UDP-GlcNAc to
the serine and threonine residues of proteins through a beta-
glycosidic O-linkage, while O-GlcNAcase (OGA) hydrolyzes
O-GlcNAc from proteins (Hart et al., 2011). OGT and OGA are
highly regulated to prevent unnecessary O-GlcNAc cycling (Se-
kine et al., 2010). Here we report thatO-GlcNAcylation and circa-
dian clock are reciprocally regulated and that O-GlcNAcylation
modulates CLOCK-dependent transcriptional activity by post-
translationally regulating components of the molecular clock.etabolism 17, 291–302, February 5, 2013 ª2013 Elsevier Inc. 291
Figure 1. Characterization of GSK3b by ATP Analog-Specific Chemical-Genetic Method
(A) Representative double-plotted actograms of daily wheel-running activity for GSK3bAS/AS and WT littermate mice. 1-Na-PP1 treatment was initiated after
1 week in constant darkness and administered daily for a week. The arrow on each actogram indicates the beginning of inhibitor treatment. 1-Na-PP1 treatment
lengthens the circadian period of GSK3bAS/AS mice in constant darkness from t = 24.0 ± 0.12 hr (no inhibitor; n = 10) to t = 24.5 ± 0.1 hr (with inhibitor; n = 6,
p < 0.01). 1-Na-PP1 treatment does not affect circadian period length in WT littermates (t = 23.7 ± 0.15 hr [no inhibitor; n = 10] versus t = 23.5 ± 0.07 hr [with
inhibitor; n = 6]).
(B) Western blot demonstrates that pS9 of GSK3b oscillates at different phases in different tissues with the phase of hippocampus antiphase to the phase of liver.
(C) In vitro kinase reactions show thatWTGSK3b is unable to utilize N-6-modified ATPgS analogs (lanes 2 and 3) as phosphodonors but utilizes ATPgS (lane 1). AS
GSK3b (L132G) efficiently utilizes both unmodified (lane 4) and N-6-modified ATPgS analogs (lanes 5 and 6) and prefers N-6-phenethyl ATPgS (lane 6). Loading
controls for the substrate myelin basic protein (MBP) and GSK3b are included.
(D) GSK3b demonstrates antiphase phosphorylation of substrates in hippocampal versus liver tissue. AS GSK3b kinase was added to the protein extracts, and
kinase assays were performed in the presence of N-6-phenethyl ATPgS. After PNBM alkylation, western blot analysis was performed using the antibodies
indicated. Blots for glyceraldehyde phosphate dehydrogenase (GAPDH) demonstrate equal loading. See also Figures S1, S2, and S7 and Tables S1, S2, and S3.
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O-GlcNAc-Phospho Interplays in Circadian ClockIn addition, O-GlcNAcylation interplays with phosphorylation on
PER2, which likely plays a role in fine-tuning clock speed.
RESULTS
Rhythmic Phosphorylation of GSK3b Substrates
We developed an ATP analog-specific (AS) chemical-genetic
approach to identify direct GSK3b substrates that are involved
in circadian regulation and coupling of core clock components
to input-output pathways. To verify the effect of GSK3b on the
circadian clock in vivo, we obtained AS GSK3b knockin mice
(GSK3bAS/AS, TaconicArtemis). Using analogs of the general
kinase inhibitor (PP1) that specifically inhibit AS, but not wild-
type (WT) kinases, kinase activity can be specifically, rapidly,
and reversibly inhibited (Bishop et al., 2000). Wheel-running
activity of GSK3bAS/AS mice was analyzed after entrainment in
a 12 hr light/12 hr dark cycle (12L/12D) for 1 week. These mice
showed a statistically significant lengthening of period versus292 Cell Metabolism 17, 291–302, February 5, 2013 ª2013 Elsevier InWT controls (24 versus 23.7 hr) in constant darkness (DD) (Fig-
ure 1A), suggesting that the engineered mutation produces an
AS GSK3b kinase with altered enzyme activity. This is consistent
with the observation that AS GSK3b enzyme activity is reduced
when compared with WT GSK3b by an in vitro kinase assay
(Figures S1A and S1B). AS GSK3b is inhibited by the 1-Na-PP1
inhibitor both in vitro in a concentration-dependent manner (Fig-
ure S1C) and in vivo (Figure S1E), whereas WT GSK3b is not
affected by 1-Na-PP1. Interestingly, after treatment with the
AS GSK3b inhibitor (1-Na-PP1), the period was further length-
ened to 24.5 hr (versus 24 hr in GSK3bAS/AS without inhibitor; Fig-
ure 1A). This finding is congruent with previous data using lithium
(Abe et al., 2000; Duez and Staels, 2008). Since lithium acts on
targets other than GSK3b (O’Brien and Klein, 2009), the data
from the GSK3bAS/AS mice suggest that specific inhibition of
GSK3b leads to lengthening of the circadian period.
GSK3b S9 phosphorylation (inactive GSK3b) demonstrates
robust circadian oscillation (Iitaka et al., 2005). In order to testc.
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peripheral tissues, hippocampus and liver tissues were obtained
from WT mice (Figure 1B). Hippocampus was used instead of
suprachiasmatic nucleus (SCN) due to the ease of anatomical
dissection and the need to obtain a sufficient quantity of tissue
for proteomic analysis. Phosphorylation of GSK3b S9 in hippo-
campus peaks at subjectivemorning (circadian time [CT] 0, lights
on or ‘‘dawn’’ in the light/dark cycle) and is antiphase to liver
where it peaks at subjective evening (CT12, lights off or ‘‘dusk’’
in the light/dark cycle), consistent with previous findings that
kinases demonstrate tissue-specific and time-specific activities
(Kategaya et al., 2012). To analyzewhether GSK3b activity corre-
lates with the substrates it phosphorylates, we isolated protein
extracts from the hippocampus and liver of WT mice at CT0
and CT12. Recombinant AS GSK3bwas added to hippocampus
and liver protein extracts together with N6-phenethyl ATPgS. AS
GSK3b enzyme prefers ATPgS analogs (N6-benzyl ATPgS and
N6-phenethyl ATPgS) as thiophospho-donors, whereas these
analogs are not accepted by WT GSK3b (Figure 1C). Thiophos-
phorylated substrates are then alkylated for recognition by a
thiophosphate ester-specific antibody (Figures S2A and S2B)
(Allen et al., 2005). Substrate phosphorylation patterns by AS
GSK3b showed dramatic differences between the two tissues
and at different CTs when assessed by western blotting (Fig-
ure 1D). The intensity of substrate phosphorylation directly
correlated with the GSK3b activity in a circadian manner (the
time point with high GSK3b activity in each tissue also showed
the highest phosphorylation of substrates).
Analog-Specific GSK3b Substrate Identification
We performed kinase reactions of analog-specific substrate
labeling by recombinant AS GSK3b to identify targets from the
liver and hippocampus proteomes (at time of peak GSK3b-medi-
ated phosphorylation CT0 in liver and CT12 in hippocampus)
(see Figure 1D). This procedure was performed three times
with protein extracts from mouse hippocampus and twice with
extracts from mouse liver. In the samples with AS GSK3b, 343
and 124 potential GSK3b substrates were identified by mass
spectrometry (MS) from the hippocampus and liver, respectively.
Eighty-six of these proteins were found in both (Tables S1 and
S2). Of the 343 and 124 proteins in these tissues, 145 and 69
of them were found only in samples with AS GSK3b, but not in
samples with WT GSK3b, and 30 of them were identified in
both the hippocampus and liver (Tables S1 and S3). To validate
the effectiveness of this approach, we experimentally examined
two proteins, zona occludens protein 1 (ZO1, Figure S2C) and
PPP1R9B (Figures 2A and S2D), and confirmed them as
substrates of GSK3b. Results from detailed bioinformatic anal-
yses for the proteomic screens can be found in Tables S1, S2,
and S3. Proteins identified in the AS GSK3b hippocampus-posi-
tive-only and AS GSK3b liver-positive-only were further exam-
ined in the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database (http://www.genome.jp/kegg) to reveal path-
ways that are potentially regulated by GSK3b (Figure S7).
Many previously known GSK3b-involved pathways, together
with additional pathways, were found through this approach,
further highlighting the interconnectedness of various regulatory
mechanisms. Collectively, these results suggest that daily timing
is an important parameter controlling GSK3b substrate speci-Cell Mficity and that tissue-specific circadian phosphoregulation of
GSK3b substrates may play important roles in the regulation of
GSK3b-dependent physiological pathways.
GSK3b Regulates OGT Activity
Intriguingly, OGT was one of the GSK3b substrates that was
identified in the chemical-genetic screen (Table S1 and Fig-
ure S2E). The covalent dynamic modification of O-GlcNAc to
proteins by OGT has emerged as a common posttranslational
modification that is as abundant as phosphorylation within the
nucleus and cytoplasm (Torres and Hart, 1984). To validate
OGT as an authentic GSK3b substrate, OGTwas immunoprecip-
itated from brain extracts of WT mice using anti-OGT antibody.
The precipitants were then subjected to WT or AS GSK3b kinase
reactions with the ATPgS N6-benzyl analog followed by SDS-
PAGE, and western blots were probed with thiophosphate
ester-specific antibody. In the presence of ATPgS N6-benzyl
analog, OGT was phosphorylated by AS GSK3b (Figure 2A).
In addition, OGT was phosphorylated by GSK3b using in vitro
32P-labeled ATP (Figure 2B), demonstrating that OGT is
a GSK3b substrate.
Mass spectrometry was then employed to identify where
GSK3b phosphorylates OGT. OGT, in the presence or absence
of GSK3b, was digested with trypsin before the peptides were
analyzed by tandem mass spectrometry to identify modified
peptides. OGT was found to be phosphorylated on S3 or S4
(data could not distinguish between these potential sites) (Fig-
ure 2C, left panel). Extracted ion chromatograms for the intensity
of this phosphorylated peptide in the two samples showed a
significant increase in the presence of GSK3b, suggesting that
this site is modified by GSK3b (Figure 2C, right panel). Interest-
ingly, MS analysis also revealed that both S3 and S4 (but
probably not at the same time) of OGT can be O-GlcNAc modi-
fied (Figure 2D). Hence, phosphorylation by GSK3b and
O-GlcNAcylation must compete with and regulate each other
at this N-terminal site of OGT.
OGT activity was next measured in the presence and absence
of GSK3b to reveal whether phosphorylation byGSK3b regulates
OGT activity. Indeed, OGT activity was enhanced with the pres-
ence of GSK3b phosphorylation (Figure 2E, OGT versus pOGT).
To test whether phosphorylation of S3 and S4 on OGT by GSK3b
is responsible for the enhanced activity, we mutated S3 and S4
to either alanine or aspartate (tomimic a constitutively phosphor-
ylated state) before the kinase assays. Increased OGT activity by
GSK3b was blocked when S3 and S4 were mutated to alanine,
providing evidence that phosphorylation on these two amino
acids is necessary for the effect of GSK3b on OGT. Interestingly,
when S3 and S4 were mutated to aspartate, OGT activity
increased slightly in the absence of GSK3b but significantly in
the presence of GSK3b, suggesting that other phosphorylation
sites on OGT are needed for the complete activation of OGT
activity by GSK3b.
Manipulating O-GlcNAcylation Levels Regulates Period
Length in Both Mice and Drosophila
Since cyclic posttranslational modifications such as phosphory-
lation (Chiu et al., 2011; Xu et al., 2007), acetylation (Hirayama
et al., 2007), SUMOylation (Cardone et al., 2005), and poly(ADP-
ribosyl)ation (Asher et al., 2010) are known to regulate clocketabolism 17, 291–302, February 5, 2013 ª2013 Elsevier Inc. 293
Figure 2. OGT Activity Is Regulated by GSK3b
(A) Kinase assays for mouse brain extracts from WT GSK3b or AS GSK3b were visualized by silver staining (top right panel) or by western blot against
thiophosphate ester antibody (top left panel). Western blots of the same brain extracts probed with antibodies against GSK3b, OGT, and PPP1R9B (middle
panels). Kinase reactions of brain extracts were immunoprecipitated by antibodies for PPP1R9B or OGT, followed by western blot against thiophosphate ester
antibody (bottom panel). PPP1R9B and OGT were specifically phosphorylated by AS GSK3b, but not by WT GSK3b.
(B) In vitro phosphorylation of OGT by GSK3b in the presence of radioactive ATP (left panel). Proteins used were detected by western blotting probed with
anti-OGT and anti-GSK3b antibodies (right panel).
(C) Increased phosphorylation of OGT N-terminal peptide by GSK3b. Extracted ion chromatograms of the mass-to-charge (m/z) ratio of the phosphorylated
version of the tryptic peptide spanning residues 2–17 of the protein OGT shows a significantly increased level upon GSK3b treatment (right panel). CID
fragmentation spectrum determines the phosphorylation to be present on either S2 or S3 of the peptide (i.e., S3 or S4 of the OGT protein) (left panel).
(D) OGT can beO-GlcNAc modified on S2 or S3 of the peptide. Electron-transfer dissociation (ETD) fragmentation spectrum of a singly GlcNAc-modified version
of the tryptic peptide spanning residues 2–17 of the protein OGT shows amixture spectrum, demonstratingmodified versions where S2 and S3 of the peptide are
both present.
(E)O-GlcNAcylation in vitro assay.O-GlcNAc transferase activity was measured using affinity-purified OGT, in the presence or absence of GSK3b, and UDP-[3H]
GlcNAc. OGT activity was enhanced by the presence of GSK3b (pOGT). S3 and S4 of OGT weremutated to either alanine (S3AS4A) or aspartate (S3DS4D) for the
assay. CKII peptide and control peptide were used as substrates in the assay. 3HDPM: 3H Disintegrations per minute. Error bars indicate the mean ± SE.
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2009), we investigated whether O-GlcNAcylation affects circa-
dian rhythmicity. We first used primary embryonic fibroblast cells
from Per2-luciferase mice (Yoo et al., 2005) and synchronized
them with glucocorticoids followed by treatment with PUGNAc
(OGA inhibitor), Alloxan (OGT inhibitor), or a pool of four
siRNAs against OGT. Interestingly, OGT inhibitor and OGT
siRNA (decreased O-GlcNAcylation) shortened, while OGA
inhibitor (increased O-GlcNAcylation) lengthened the circadian
rhythmicity of Per2-Luc oscillation (Figures 3A, 3B, and S3C).
We then confirmed period shortening with OGT conditional
knockout mice (Figures 3C, S3A, and S3B) to reduce OGT levels
in vivo (knockout of OGT in mice causes early embryonic
lethality) (Shafi et al., 2000).
Next, we asked whether O-GlcNAcylation is conserved as
a regulatory mechanism in Drosophila circadian clock. We
crossed tim(UAS)-Gal4 (Martinek et al., 2001) with UAS-RNAiOgt
or UAS-RNAiOga to downregulate and UAS-Ogt or UAS-Oga to
overexpress OGT and OGA, respectively, in Drosophila for294 Cell Metabolism 17, 291–302, February 5, 2013 ª2013 Elsevier Inbehavioral analyses. Ogt knockdown and Oga overexpression
both resulted in period shortening, while Oga knockdown and
Ogt overexpression both led to period lengthening (Figures 3D
and S3D). Together, these results suggested that O-GlcNAcyla-
tion is regulating the circadian clock in mice and flies and raised
the possibility that clock proteins may be the direct targets of
O-GlcNAcylation.
O-GlcNAc Modification of Drosophila and Mammalian
Clock Components
Using Drosophila Schneider 2 (S2) cell culture, we identified that
dClk and dPer areO-GlcNAcylated (Figures 4A and 4B). dClk-V5
coimmunoprecipated with Ogt and Oga (Figure 4C) from S2
cells, supporting the possibility that dClk is a target of Ogt/
Oga-dependent, reversible O-GlcNAcylation. To show that
mammalian clock proteins are also O-GlcNAc modified, human
PER2-His and human OGT-Flag were coexpressed. PER2 was
detected byO-GlcNAc antibody after anti-His immunoprecipita-
tion, whereas O-GlcNAcylated PER2 was not detected in thec.
Figure 3. O-GlcNAcylation Levels Regulate Period Length
(A) Alloxan (1 mM; OGT inhibitor) shortens (22.2 hr ± 19 min) and PUGNAc (100 mM; OGA inhibitor) lengthens (25.6 hr ± 15 min) the circadian period of primary
fibroblasts extracted from Per2-Luc reporter mice. For control, the periods of Per2-Luc fibroblasts were measured as 24.2 hr ± 21 min. Concentrations of Alloxan
and PUGNAc were experimentally tested in pilot experiments (data not shown). A representative of experiments repeated in triplicate is illustrated.
(B) A pool of fourOGT siRNAs shortensPer2-Luc fibroblast periods to 22.5 hr ± 20min compared to the control siRNA pool at 24.4 hr ± 30min. A representative of
experiments repeated in triplicate is illustrated. OGT andO-GlcNAc levels in the control and siRNA cells were determined by western blotting shown to the right.
(C) OGTF/Y-rtTA-actin/tetO-cre (conditional knockout) and OGTF/Y/tetO-cre (control) mice were entrained in a 12 hr dark/12 hr light cycle. The mice were re-
leased to constant darkness before doxycycline (2 mg/ml) was supplemented into drinking water. Representative locomotor activity recordings of indicated
mouse genotypes are presented. For visualization, 2 days are plotted per row. Quantifications of period length by hours are shown in the right panel. n = 8 for both
mice genotypes.
(D) Representative locomotor activity recordings and periodograms of indicated fly genotypes over circadian time. For visualization, 2 days are plotted per row.
On top of the panels, the subjective light (gray bar) and dark (black bar) phases are indicated. Numbers in the oscillation graphs indicate t, the expressed period of
the free-running rhythm in constant darkness, of flies with the indicated genotype. Details and quantifications are specified in Table S4. Controls for (A), (C), and
(D) are shown in Figure S3. Error bars represent SEM. See also Figure S3.
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cylation of PER2 is specific (Figure 4D). In the presence of
OGA inhibitor (PUGNAc) in the lysis buffer, PER2-His was also
detected as O-GlcNAc modified without cotransfection with
OGT, further supporting that PER2 ismodified byO-GlcNAc (Fig-
ure 4E). Immunoprecipitation was next performed with mouse
liver extracts using anti-O-GlcNAc antibody, and western blot
analysis indicated O-GlcNAcylation of both mouse PER2 and
OGT in vivo (Figure 4F). Similarly, mouse CLOCK is likely
O-GlcNAcylated by OGT and de-O-GlcNAcylated by OGA in
HEK293 cells (Figure 4G). Usingmouse liver extracts, OGA coim-
munoprecipitated with CLOCK at circadian times CT8 and CT20
(Figure 4H), indicating that CLOCK interacts with OGA and is
likely a target of OGT/OGA-dependent O-GlcNAcylation.
O-GlcNAcylation Modulates dClk and dPer
Transcriptional Activities
To gain further insight into the effect of O-GlcNAcylation on dClk
in circadian regulation, we employed a luciferase assay to
measure dClk-dependent E-box activation of the per promoterCell Min the presence of Ogt or Oga (Figure 5A) and demonstrated
that de-O-GlcNAcylated dClk activates and O-GlcNAcylated
dClk represses E-box-dependent per-luc activation more than
basal dClk (i.e., without exogenous Ogt or Oga). Interestingly,
the transcriptional activity of dClk when dClk and dPer are
both de-O-GlcNAcylated is similar to the activity of dClk without
dPer, and the repressive effect of dPer is further enhanced when
dClk and dPer are both O-GlcNAcylated, implying that Ogt
enhances and Oga relieves dPer-dependent per-luc inhibition
through dClk. These results demonstrate that O-GlcNAc modifi-
cation of dClk transcriptional activity is integral for regulation of
the molecular clock.
Since O-GlcNAcylation modulates dClk transcriptional
activity, we next measured dTim and dPer levels. When Ogt is
overexpressed (i.e., reduced dClk transcriptional activity), both
dTim and dPer levels were reduced compared to control flies,
and their rhythm phases showed a subtle trend of delay in clock
neurons (Figures 5B and S4B). On the other hand,Ogt RNAi (i.e.,
increased dClk transcriptional activity) resulted in increased
dTim and dPer protein (Figure 5C) and RNA levels (Figure 5D),etabolism 17, 291–302, February 5, 2013 ª2013 Elsevier Inc. 295
Figure 4. O-GlcNAcylationofClockProteins
(A) dClk-V5 was transfected into S2 cells alone
or together with Ogt-Flag or Oga-Flag followed
by dClk-V5 pull-down and O-GlcNAc western
analysis.
(B) dPer-myc was transfected into S2 cells alone
or together with Ogt-Flag or Oga-Flag followed
by dPer-myc pull-down and O-GlcNAc western
analysis.
(C) dClk-V5 was transfected into S2 cells alone or
together with Ogt-Flag or Oga-Flag, and dClk-V5
pull-down was performed using V5. Western blot
was performed with Flag antibody. IgG was used
as negative control for pull-down.
(D) Human PER2 (PER2) is O-GlcNAcylated in
HEK293 cells (upper panel). GlcNAc in the western
buffer blocks the interaction of O-GlcNAc anti-
body with PER2, indicating that PER2 is
O-GlcNAcylated (middle panel).
(E) hPER2-His or empty plasmids were trans-
fected into HEK293 cells, and pull-down was
performed with His or V5 antibodies. The OGA
inhibitor PUGNAc was included in the lysis buffer,
and western blot was probed with O-GlcNAc (left
panel) or PER2 (right panel) antibodies. In the
presence of PUGNAc, PER2 is O-GlcNAcylated
without additional OGT (left panel). Cells trans-
fected with empty plasmids were included as
negative controls.
(F) Western analysis for immunoprecipitants using
anti-O-GlcNAc frommouse liver extracts with anti-
PER2 (mouse PER2) and anti-OGT antibodies
demonstrate that PER2 is O-GlcNAc modified.
OGT is auto-O-GlcNAcylated and serves as
a positive control. IP with IgG was used as a
negative control.
(G) mCLOCK (CLK) isO-GlcNAcylated by OGT and de-O-GlcNAcylated by OGA. CLK-Flag was transfected into HEK293 cells either alone or together with OGA
or OGT-V5 followed by Flag pull-down and O-GlcNAc western analysis.
(H) CLOCK protein interacts with OGA in themouse liver. CLOCK protein was immunoprecipitated from themouse liver at CT8 andCT20.Western blot of the CLK
pull-down was probed with CLK and OGA antibodies (bottom panel). Inputs are shown over the time course including CT8 and CT20 (top panel).
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together, these results point to the necessity for balanced OGA
and OGT activities and tightly controlled levels of O-GlcNAc-
modified clock components for proper clock function.
Competition of O-GlcNAcylation and Phosphorylation
for the PER2 S662–S674 Region
Human PER2 S662–S674 is a critical site for regulating clock
speed by serial phosphorylation of multiple residues; a serine
(S662) to glycine mutation leads to hypophosphorylation of this
region and causes familial advanced sleep-phase disorder
(Toh et al., 2001). We hence investigated the possibility that O-
GlcNAcylation interplays with phosphorylation at S662–S674,
and tandem mass spectrometry (MS/MS) analyses were carried
out to identify O-GlcNAc sites on PER2 focusing on this region
(Figure 6A). O-GlcNAcylation can occur on S662, and this only
occurs together with O-GlcNAcylation on S671 (Figure 6A),
implying a potential antagonism of O-GlcNAcylation with phos-
phorylation in this region. Interestingly, O-GlcNAc sites found
with our method concentrate in the CK1 binding domain (S566,
S580, S653, S662, S668, S671, and T734) and in the C terminus
(T965, S983, and T1180) of PER2 (Figure 6B). To investigate
the possible interplay between phosphorylation andO-GlcNAcy-296 Cell Metabolism 17, 291–302, February 5, 2013 ª2013 Elsevier Inlation on PER2 S662–S674, HEK293 cells were transfected
with PER2-His alone or cotransfected with either OGT or OGA,
followed by immunoprecipitation with His antibody. Western
blot analysis using an antibody specific for phospho-S662
PER2 revealed that phosphorylated S662 PER2 level was
reduced in cells cotransfected with PER2 and OGT, while
O-GlcNAcylation was increased on PER2, suggesting that
O-GlcNAcylation can block S662 phosphorylation (Figure 6C).
However, neither OGT nor OGA interfered with the binding of
CK1 to PER2. PER2 peptides (Xu et al., 2007) containing either
S662 or pS662 were then used in an O-GlcNAcylation assay,
and pS662 peptides significantly reduced the capacity for
O-GlcNAcylation (Figure 6D), supporting the competitive inter-
play between phosphorylation and O-GlcNAcylation at S662.
Consistent with the finding for dClk and dPer transcriptional
activity (Figure 5A), OGT inhibited CLK-BMAL1 transcription
and further enhanced PER2 repressor activity (Figure S5). This
is congruent with the previous finding that PER2-S662G is
a stronger repressor than WT PER2 (Xu et al., 2007), and as
expected, repressor activity of PER2-S662G is not modulated
by OGT (Figure S5). Taken together, these data strongly suggest
that O-GlcNAcylation and phosphorylation compete at S662 of
PER2 to fine-tune its activity.c.
Figure 5. Functional Effects of O-GlcNAcy-
lation on dClk
(A) The effects ofOga andOgt on dClk-dependent
per-luc activity. Luciferase assayswere performed
in triplicate on at least three independent occa-
sions.
(B and C) dTim, dPer, and dOgt protein levels
under Ogt overexpression (B) and Ogt RNAi (C) as
illustrated by western analyses (left panels) and
quantifications (right panels).
(D) Quantification of Per, Tim, and VrimRNA levels
from Ogt RNAi flies by qRT-PCR. Three indepen-
dent experiments were used for each circadian
time point. Error bars represent SEM. See also
Figure S4.
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O-GlcNAc-Phospho Interplays in Circadian ClockSince O-GlcNAcylation is the direct readout for the hexos-
amine biosynthetic pathway (HBP; converting glucose to UDP-
GlcNAc), a nutrient sensing pathway through glucose, we further
investigated the impact of glucose on O-GlcNAcylation and
phosphorylation of PER2 S662, S665, and S668. We employed
an in vitro system with glucose levels that were established
previously for this analysis (Lamia et al., 2009). In the presence
of high glucose, but not low glucose, OGT was able to block
the phosphorylation by CK1d of this region (Figure 6E, right
panel, lanes 3 and 4), suggesting that high glucose levels likely
increase O-GlcNAcylation, which blocks phosphorylation of
the PER2 S662–S668 region. Intriguingly, high glucose can
significantly prevent phosphorylation even in the presence of
OGA (Figure 6E, right panel, lane 6). Given the role of PER2
S662 phosphorylation in regulating human clock (Xu et al.,
2007), these results suggest that glucose metabolism and
O-GlcNAcylation modulate the circadian clock partially through
O-GlcNAcylation’s competition with phosphorylation in the
PER2 S662 region (Figure 6F).
O-GlcNAcylation Is Regulated by Circadian Clock
Since phosphorylation and O-GlcNAcylation both modify serine
and threonine residues, and multiple phosphorylation eventsCell Metabolism 17, 291–302are known to exhibit circadian oscillation,
we set out to determine whether
O-GlcNAc modification on clock proteins
also oscillates. dClk was pulled down
from the heads of yw;;dClk-V5 flies (Me-
net et al., 2010) at different circadian
time points and then immunoblotted
with O-GlcNAc antibody. Endogenous
dClk protein underwent O-GlcNAc modi-
fication in a time-dependent manner
peaking at ZT10 (Figures 7A and 7B),
though total dClk protein levels oscillate
in the opposite phase. dPer coimmuno-
precipitated with dClk (Menet et al.,
2010) and exhibited a similar rhythmic
O-GlcNAc modification pattern (Figures
7A and 7B). Similarly, dClk and dPer
O-GlcNAcylation peaked in constant
conditions at CT10–CT14 (Figures S6A
and S6B). In addition, like what was foundfor mammalian CLOCK (Figure 4G), Oga protein coimmuopreci-
pitated with the dClk/dPer complex in vivo (Figure S6B). These
results indicate that O-GlcNAc modification is likely under circa-
dian clock regulation. We next analyzed OGT and OGA protein
expression levels from liver tissues of WT mice over circadian
time. Expression levels of OGT (110 kDa) did not oscillate.
However, OGA protein exhibited an oscillating expression
pattern that peaks around CT8–CT12 (Figure 7C) (OGA mRNA
expression also oscillates with a peak at CT2.3; http://bioinf.
itmat.upenn.edu/circa). Ogt and Oga protein levels of WT fly
heads showed expression patterns similar to mouse liver
(Figures 7D and 7E). Therefore, while OGA protein levels (and
presumably total OGA activity) oscillate in a circadian manner,
OGT protein levels are constant. But OGT activity is modulated
by GSK3b (Figure 2), and GSK3b activity is known to oscillate
through S9 phosphorylation. This would imply that OGT activity
could also oscillate. Interestingly, we found that the O-GlcNAc
on OGT itself showed a possible oscillating modification pattern
through time (Figure S6E), which supports the likelihood that
OGT activity oscillates. Taken together, these data suggest
that both OGT incorporation of donor sugar nucleotides to
proteins and OGA removal of these sugar nucleotides occur in
a circadian time-dependent manner., February 5, 2013 ª2013 Elsevier Inc. 297
Figure 6. Competition of O-GlcNAcylation
and Phosphorylation for Residues in the
PER2 S662–S674 Region
(A) MS/MS spectrum of the doubly O-GlcNAc-
modified PER2 S660–S682 region. Full-length
human PER2 was purified using FLAG affinity tag
from the HEK293 cells before being subjected to
MS/MS analysis. Modified c4 and c5 ions localize
one of the modification sites to S662, while the
mass shift between unmodified z + 111 and
modified z + 112 pinpoints the secondmodification
site to S671.
(B) MS/MS identified O-GlcNAc sites S566, S580,
S653, S662, S668, S671, T734, T965, S983, and
T1180 (labeled in red) for PER2 in the CK1 binding
domain (amino acids 557–771) and C terminus.
The identified S662, S668, and S671 O-GlcNAc
sites are also CK1 phosphorylation sites.
(C) Western blots performed with antibodies indi-
cated on the left demonstrating that the presence
of OGT inhibits PER2 S662 phosphorylation, but
the presence of either OGT or OGA does not block
CK1 binding to PER2.
(D) In vitro O-GlcNAcylation assay using affinity-
purified OGT peptides and UDP-[3H]GlcNAc.
O-GlcNAcylation of pS662 PER2 peptide is signif-
icantly reduced compared to nonphosphorylated
S662 PER2 peptide. CKII and Vangl1 peptides
served as positive and negative controls, respec-
tively. Error bars indicate the mean ± SE.
(E) The PER2 S662 region is regulated by both
O-GlcNAcylation and phosphorylation. PER2 was
transfected alone (lane 1) or with OGT (lane 2),
CK1 (lane 3), OGT and CK1 (lane 4), OGA (lane 5),
and OGA and CK1 (lane 6) in the presence of low
(left panel) or high (right panel) glucose into
HEK293 cells. Western blots of protein extracts
from these cells were probed with antibodies
indicated on the left of the panels.
(F) Proposed model for competitive regulation
by O-GlcNAcylation and phosphorylation of the
PER2 S662–S674 region. When PER2 S662–S674
is hypophosphorylated (i.e., O-GlcNAcylated), it
is known to be a stronger repressor with lower
protein stability, whereas when this region is
hyperphosphorylated, it is a weaker repressor
with higher stability (Xu et al., 2007). See also
Figure S5.
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We developed an analog-specific chemical-genetic proteomic
approach to characterize theGSK3b-dependent circadian phos-
phoproteome and identified OGT as a GSK3b substrate. Here,
we found that OGT is phosphorylated at S3 or S4 by GSK3b
and that O-GlcNAcylation of OGT also occurs on the same or
neighboring serine residues, suggesting interacting phosphory-
lation and O-GlcNAcylation events on OGT itself.
OGT is expressed constitutively, while OGA levels oscillate
with a peak around CT8–CT12, and phosphorylation of OGT by
GSK3b increases OGT activity. Given that GSK3b activity oscil-
lates through circadian time, it implies that the activity of OGT
oscillates. OGT activity is likely further regulated by additional298 Cell Metabolism 17, 291–302, February 5, 2013 ª2013 Elsevier Inmodulations including auto-O-GlcNAcylation. Intriguingly, the
O-GlcNAc modification patterns of OGT support a possibility
for oscillating OGT activity. Moreover, OGA activity may also
be regulated by other factors and posttranslational modifica-
tions. Interestingly, OGA was also identified in our GSK3b chem-
ical-genetic screen (Table S1). Together, all these pathways
contribute to the determination of O-GlcNAcylation oscillation
patterns of clock components. Hence, it is possible that the
peak of O-GlcNAc modification of clock proteins may not have
obvious correlation with the peak of OGA expression. This intri-
cate regulatory system is therefore multilayered and consistent
with the notion that delicately modulated mechanisms are
required for circadian regulation at different levels. Recently,
O-GlcNAcylation was shown to modulate both the Drosophilac.
Figure 7. O-GlcNAcylation Is Regulated
by Circadian Clock
(A) dClk was pulled down from yw;;dClk-V5 flies
(one extra copy of Clk) at different zeitgeber times
(ZT) prior to being immunoprecipitated by V5
antibody. Immunoprecipitated preparations were
run on identical gels. Western blots of these gels
were then immunoblotted by dClk, dPer, Tubulin
(left panels), and O-GlcNAc (right panels) anti-
bodies, separately.
(B) Quantification of immunoprecipitated proteins
(left panel) and O-GlcNAcylated proteins normal-
ized with immunoprecipitated protein levels (right
panel).
(C) Immunoblotting indicates that OGA protein
levels oscillate over 24 hr, and OGT expression
levels (110 kDa band) are constant over 24 hr in
extracts of mouse liver tissue.
(D) Oga shows oscillation over 24 hr, and Ogt
expression is constant in protein extracts from
WT fly heads.
(E) Quantification of (D). Error bars represent SEM.
See also Figure S6.
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O-GlcNAc-Phospho Interplays in Circadian ClockPer (Kim et al., 2012) and the mammalian BMAL1 (Durgan et al.,
2011) in regulating circadian clock. Though some discrepancies
exist among different reports, one consistent finding is the
modulation of circadian period length by the level ofO-GlcNAcy-
lation. In addition, OGT overexpression leading to reduction in
Period protein levels was found by two independent studies
(by us and the Durgan group). This modulation of PER levels
by O-GlcNAcylation could be one of the major reasons for the
observed period changes, since it has been shown that PER
rhythmic abundance is the driving force for the clock oscillation
(Chen et al., 2009; Yu et al., 2006). Additional work is needed to
identify site-specific roles of O-GlcNAcylation and then their
interplay with phosphorylation and other posttranslational modi-
fications in clock proteins in order to further reveal the complex
regulatory mechanisms of the circadian rhythms.
Protein O-GlcNAcylation has been shown to regulate tran-
scriptional machinery (Ozcan et al., 2010). For example, the
RNA polymerase (pol) II C-terminal domain is modified by both
phosphorylation and O-GlcNAcylation in a mutually exclusive
manner. It was proposed that transcriptionally inactiveO-GlcNA-
cylated RNA pol II holoenzyme localizes to promoters in a poised
state but can only effect transcriptional elongation when the
C-terminal domain O-GlcNAc is removed and becomes hyper-Cell Metabolism 17, 291–302phosphorylated upon gene activation
(Comer and Hart, 2001). It is possible
that a similar mechanism is utilized to
fine-tune the activity of Clock transcrip-
tional function. Another possibility is that
the balance between O-GlcNAcylation
and phosphorylation of Clock modulates
interactions between Clock and its
binding partners (such as repressors) in
a similar manner to what has been shown
for Myc (Kamemura et al., 2002). Our
finding that O-GlcNAcylation of the
PER2 S662 regulatory region blocksCK1-dependent PER2 phosphorylation also supports the latter
hypothesis. The phospho-O-GlcNAc switch therefore provides
a possible mechanism for tight control of the molecular clock in
order to maintain precise daily rhythms. Many questions remain,
such as how do O-GlcNAcylation and other posttranslational
modifications (in addition to phosphorylation) synergistically
regulate the intricate circadian clock? CLOCK has acetyltrans-
ferase activity and regulates chromatin remodeling through the
acetylation of BMAL1 (Hirayama et al., 2007), and Ogt has been
identified as a repressor from the polycomb complex (Gambetta
et al., 2009; Myers et al., 2011). Thus, the fact that clock proteins
are modified by OGT/OGA connects the HBP and epigenetics
(Polycomb as a protein complex for chromatin modulation) to
the circadian core clock loop. Since protein O-GlcNAcylation is
regulated principally by substrate UDP-GlcNAc availability, and
HBP (a nutrient sensor) flux is known to parallel substrate
(glucose) availability, our results showing that high glucose
blocks CK1-dependent PER2 phosphorylation (Figure 6E) raise
the intriguing possibility that the HBP and O-GlcNAc turnover
represent a glucose-dependent mechanism for regulating circa-
dian clocks and support the connection for metabolic pathways
and molecular clock. Interestingly, circadian misalignment was
shown to increase blood sugar concentrations in human (Buxton, February 5, 2013 ª2013 Elsevier Inc. 299
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O-GlcNAc-Phospho Interplays in Circadian Clocket al., 2012; Scheer et al., 2009), indicating that the timing of
nutrient intake needs to be correlated with the timing of circadian
expression of genes responsible for metabolism. Our finding that
glucose levels through O-GlcNAcylation can modulate circadian
clock protein further provides evidence that nutrient intake (and
its timing) and circadian clock have a closely maintained cooper-
ative relationship. In total, our data represent a further step
toward a greater understanding of the complex mechanisms
that control our bodily circadian functions in a highly coordinated
manner.
EXPERIMENTAL PROCEDURES
Plasmid Constructs
See Supplemental Experimental Procedures.
Kinase Assay
Nonradioactive
Glutathione S-transferase (GST) fusion of either WT GSK3b or AS GSK3b
protein was expressed in E.coli and purified by Glutathione Sepharose 4B
(GE Healthcare) (Kosuga et al., 2005). The GST tag was then removed by
PreScission Protease digestion (GE Healthcare). AS GSK3b kinase activity
was comparable to commercial GSK3b kinase activity (New England Biolabs).
For kinase assay, 100 nM recombinant WT GSK3b or AS GSK3b was used
(Allen et al., 2007). Kinase assay buffer contains 20 mM HEPES (pH 7.5),
10 mM MgCl2, 0.01 mM DTT, 0.2 mM ATPgS (or ATPgS analogs), 1 mM
GTP, and 1 mM ATP. Either 2 mg MBP or 5 mg GSK3b was used as AS
GSK3b substrate. Reactions were incubated for 10 min at room temperature
(RT) and terminated by 2.5 mM EDTA. Alkylating agent, 2 mM p-nitrobenzyl-
mesylate (PNBM), in dimethyl sulfoxide (DMSO) was added, and reactions
were incubated for 1.5 hr at room temperature. Laemmli buffer was added,
and the samples were analyzed by western blotting.
Radioactive
Recombinant human OGT protein (350 ng; OriGene) was phosphorylated by
1000 U GSK3b (New England Biolabs) for 15 min at 30C in 13 GSK3 buffer
(New England Biolabs) and supplemented with 0.5 ml 32P-labeled ATP (3,000
Ci/mmol) and 200 mM of cold ATP. For negative control reactions, OGT was
incubated without GSK3b. Proteins were separated by 4%–12% Tris-HCl
gels (Bio-Rad Laboratories) and transferred to nitrocellulose membrane for
autoradiography or western blot.
Assay for OGT Activity
Recombinant human OGT-V5, S3AS4A Ogt-V5, or S3DS4D Ogt-V5 (100 ng)
was purified from HEK293 cells. OGT was eluted with V5 peptide from the
agarose beads and was phosphorylated by GSK3b (New England Biolabs)
for 1 hr at RT in the presence of ATP in 13 GSK3b buffer with 200 mM of
cold ATP. For the unphosphorylated OGT, the reactions were carried out
without ATP. For the OGT activity assay, pOGT and OGT were incubated
with 500 mM of CKII peptide (340PGGSTPVSSANMM352) in the presence of
0.02 mCi of UDP-[3H]GlcNAc (NEN Life Science Products) in 25 mM 50 AMP,
500 mM sodium cacodylate (pH 6.0), and 10 mM 1-amino-GlcNAc (Sigma-
Aldrich). Reactions were incubated for 30 min at RT and stopped by 50 mM
formic acid. Reactions were purified with Sep-Pak C18 Vac cartridges
(Waters), peptides were eluted by methanol, and 3H incorporation to the
peptide was measured by scintillation counter. Reactions were performed
in triplicates. Phospho-662 PER2 and PER2 peptides were described
previously (Xu et al., 2007). Vangl1 peptide 517RLQSETSV524 was used as
the negative control.
Cell Culture
For transient protein expression, HEK293 cells were transfected with the
following plasmids: hPER2-His, hS662G PER2-His, hPER2-Flag, mCLOCK-
Flag, mBMAL1, hOGT-V5, hOGA-Flag, orCK1d-myc. FuGENE HD transection
reagent was used according to the manufacturer’s protocol (Roche). TAP
buffer supplemented with 100 mMPUGNAc was used for immunoprecipitation
(IP) (Angers et al., 2006). pGL3-TAT (Meijsing et al., 2009) and per2-luc plasmid300 Cell Metabolism 17, 291–302, February 5, 2013 ª2013 Elsevier In(Kaasik and Lee, 2004) were used for luciferase assay. Anti-FlagM2 Affinity Gel
(Sigma-Aldrich) or His antibody (Sigma-Aldrich) was used for pull-down.
Mouse Models
All experiments with mice were conducted according to protocols approved
by the Institutional Animal Care and Use Committee at the University of Cali-
fornia, San Francisco. GSK3bAS/AS homozygous knockin mice were obtained
from Taconic. To specifically inhibit GSK3bAS/AS with AS kinase inhibitors such
as 1-Na-PP1, GSK3bAS/AS knockin mice in wheel-running cages were en-
trained in a light/dark cycle (12 hr light/12 hr dark) for 1 week. Mice were
then released into constant darkness for 2 weeks. Intraperitoneal injection of
1 mM 1-Na-PP1 (100 mM per 25 g body weight) was given at CT12 every
day for a week beginning after 1 week in constant darkness. Ogttm1Gwh/Y
mice were a gift from Dr. J. Marth (Shafi et al., 2000). TetO-cre and actin
rtTA mice were obtained from the Jackson Laboratory (Perl et al., 2002; Sarin
et al., 2005). Five OGTF/Y/tetO-cre/and five OGTF/Y-rtTA-actin/tetO-cremice in
wheel-running cageswere entrained in a light/dark cycle (12 hr light/12 hr dark)
for 1 week. Mice were then released into constant darkness for 3 weeks, and
doxycycline hydrochloride (Sigma-Aldrich) was supplied in the drinking water
at a concentration of 2 mg/ml. The doxycyline-containing water was renewed
every 3 days. Wheel-running activity was recorded and analyzed by ClockLab.
Fly Cell Culture, Transgenic Fly, and Locomotor Behavior Analysis
Drosophila luciferase assay was carried out as described previously (Kivima¨e
et al., 2008). Knockdown and overexpression of Ogt (CG10392) and Oga
(CG5871) was performed using Drosophila. For knockdown, UAS-RNAi lines
of Ogt (18610, 18611) and Oga (41823, 41822) were obtained from the Vienna
Drosophila RNAi Center (Dietzl et al., 2007). To enhance the knockdown effect,
transgenic flies were crossedwith UAS-Dicer2. The Tim-UAS-GAL4 driver was
used to knockdown or overexpress Ogt and Oga (Blau and Young, 1999).
UAS-HA-Ogt (or UAS-Ogt) and UAS-HA-Oga (or UAS-Oga) flies were gener-
ated to overexpress Ogt and Oga using the GAL4 system (Genetic Services,
Inc). Analysis of locomotor activity of individually housed male flies (or virgin
females) was performed in constant darkness at 25C using the Drosophila
Activity Monitoring System (TriKinetics). Per0 flies were obtained from the
Drosophila Stock Center (Bloomington, IN), and yw;;Clk-V5 flies were obtained
from a previous report (Menet et al., 2010).
LumiCycle Analysis
Primary fibroblasts from Per2-luc mice (Yoo et al., 2004) at E13–E14 were ex-
tracted, cultured, and treated with 0.1 mM dexamethasone (Sigma-Aldrich) to
reset circadian clock. PUGNAc (Toronto Research Chemicals, Inc.) was used
to inhibit OGA, and Alloxan (Sigma-Aldrich) was used to inhibit OGT. Pools of
four siRNAs of OGT were used and delivered with Accell siRNA reagent to
primary Per2-luc fibroblasts (Dharmacon). Luciferase reporter activity was
measured in the LumiCycle (Actimetrics).
Statistical Analysis
Significant differences were determined by applying one-tailed or two-tailed
Student’s t tests depending on the sample types. Wheel-running activity
was compared between groups using repeated standard t tests for pairwise
comparisons. Quantitative RT-PCR (qRT-PCR) results were analyzed by
Student’s t test. Error bars indicate the mean ± SE.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online at
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